Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

MHRA authorises new COVID-19 vaccine

6
SHARES

The new COVID-19 vaccine authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) contains an adjuvant and is indicated to be given to patients over 16 years.

MHRA authorises new COVID-19 vaccine Bimervax

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

MHRA authorisation of Bimervax

The COVID-19 vaccine, developed by HIPRA Human Health, combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, according to the MHRA. This is an additional ingredient designed to trigger a stronger immune response. It can be given as a booster injection in the upper arm, to those aged 16 years and over.

Clinical evidence for this authorisation is based on data from a study of 765 adults given a primary vaccination with two doses of the Comirnaty COVID-19 vaccine and who were administered with a booster dose of either Bimervax or Comirnaty. The vaccine demonstrated a strong immune response in the trial.

COVID-19 vaccines already authorised

In addition to Bimervax being authorised, since the COVID-19 pandemic, vaccines to immunise against the virus that have been approved include Comirnaty, which was authorised by the MHRA for COVID-19 patients aged six months to four years old in December 2022. The extended approval enables eligible patients to be treated with a lower dose of the vaccine compared to the dose given to patients aged five to 11 years old.

The European Commission (EC) approved AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) antibody combination in September 2022 as a treatment for COVID-19 patients in the EU.

In August 2022, the MHRA approved Moderna’s adapted vaccine for COVID-19, Spikevax bivalent Original/Omicron as a booster treatment. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 variant, in addition to the original 2020 strain.

According to the World Health Organization (WHO), the surge in vaccine supply in 2021 compared to 2019 was primarily driven by COVID-19 vaccines. This shows the industry’s ability to rapidly scale up manufacturing for vaccines in response to demand from health events such as pandemics.

UK approves Moderna’s bivalent COVID-19 vaccine

Share via
Share via